Skip To Main Content
Madson Q Almeida on Muck Rack

Madson Q Almeida

As seen in: Frontiers, Medscape, Cell Press, Journal of Endocrinology
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Madson Q

Contact Madson Q, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

A multistakeholder call for belzutifan biomarker data in advanced pheochromocytoma and paraganglioma

|
By Rodrigo A. Toledo, Carlota Arenillas, Patricia Dahia, Judith Favier, Mercedes Robledo, Anand T. Vaidya, Henri J. Timmers, Cristina L. Ronchi, Frederic Castinetti, Roderick J Clifton-Bligh, Christina Pamporaki, Ruth Casey, Madson Q Almeida, Louis J. Maher, Hussam Alkaissi, Jorge Hernando, Akiyo Tanabe, Isabelle Bourdeau, Marta Araujo-Castro, Anna-Karin Gustavsson, Joanna Grey, Anna Greene, Aaron Hansen, Irina Bancos, Scott A. Akker, William Young, Svenja Nölting, Hans K. Ghayee, Graeme Eisenhofer, Jacques W.M. Lenders, Karel Pacak, Cynthia M. Estrada-Zúñiga, Amanda Dusing, Mar Ayllón
| Cell Press Verified
Keywords belzutifan HIF-2α biomarker pheochromocytoma paraganglioma Belzutifan for advanced pheochromocytoma/paraganglioma: A milestone for rare cancers Completion of the LITESPARK-015 trial (NCT04924075i) and the U.S. Food and Drug Administration (FDA) approval of belzutifan represent a landmark for patients with advanced pheochromocytoma/paraganglioma (PPGL)ii and, more broadly, for the rare cancer community.
Open in Who Shared Issue with article?

Embryonic stem cell factor FOXD3 (Genesis) defects in gastrointestinal stromal tumors

|
By Fabio R. Faucz, Guillaume Assie, Madson Q Almeida, Anelia D Horvath
| bioscientifica.com
Endocrine-Related Cancer is committed to supporting researchers in demonstrating the impact of their articles published in the journal. The two types of article metrics we measure are (i) more traditional full-text views and pdf downloads, and (ii) Altmetric data, which shows the wider impact of articles in a range of non-traditional sources, such as social media. More information is on the Reasons to publish page.
Open in Who Shared Issue with article?

Editorial: A year in review: discussions in cancer endocrinology

|
By Facultad de Medicina, Universidad del Azuay, Madson Q Almeida, Claire Perks
| Frontiers
The Cancer Endocrinology field is continuously evolving; therefore, we tried to understand developments and perspectives on articles that have attracted attention throughout the year.
Open in Who Shared Issue with article?
See all 5 articles